ZZPZH(SH:600436) Zhong Zheng Wang·2025-12-02 07:26Core Viewpoint - The company Pizhou Pharmaceutical Co., Ltd. has been awarded the "2024 Golden Bull Most Investment Value Award," highlighting its strong comprehensive strength and sustained investment value in the competitive market [1][2]. Group 1: Award Recognition - The "Golden Bull Most Investment Value Award" is recognized as one of the most credible awards in the capital market, evaluated based on 18 key indicators across six dimensions, including enterprise scale and profitability [2]. - Pizhou has consistently received Golden Bull awards for several years, reflecting the high recognition of its comprehensive strength and long-term investment value by the judging panel [2]. Group 2: Investor Returns - The company emphasizes investor returns with a stable cash dividend policy, distributing a cash dividend of 2.97 yuan per share (including tax) for 2024, totaling 1.79 billion yuan, which is a historical high and accounts for 60% of net profit [3]. - This marks the 21st consecutive year of cash dividends since the company went public in 2003, with cumulative cash dividends nearing 8.5 billion yuan [3]. Group 3: Brand Value - As a time-honored brand, Pizhou has achieved a brand value of 42.289 billion yuan in 2024, ranking second among "Chinese Time-Honored Brands," with its brand value increasing year by year [4]. - The company has topped the "Hurun Brand List for Chinese Medical Health Brand Value" for four consecutive years and led the "Hurun China's Most Historical Cultural Heritage Brand List" for three times in 2024, showcasing its cultural depth and market influence [4][5]. Group 4: Innovation and Development - Pizhou adheres to innovation-driven development, with R&D investment reaching 270 million yuan in 2024, a year-on-year increase of 16.38% [6]. - The company is focusing on secondary development research of its advantageous products and accelerating the R&D of innovative traditional Chinese medicine and chemical drugs [6][7]. Group 5: ESG Performance - In terms of ESG (Environmental, Social, and Governance), Pizhou's performance has been recognized internationally, with its ESG rating upgraded from "BBB" to "A" by MSCI in 2024, indicating its management level is among the global industry leaders [7]. - The company has received multiple ESG-related awards, including "2024 Top 20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies" and "ESG Value Transmission Award," reflecting the market's high recognition of its sustainable development capabilities [7][8]. Group 6: Future Outlook - Pizhou aims to use this award as a new starting point to continue its development philosophy of "Upholding Integrity and Innovation, Steady Progress," focusing on business expansion, R&D innovation, and brand building [8]. - The company plans to strengthen its core product advantages and expand its market presence in cosmetics, daily chemicals, and health food sectors, contributing to the health industry and creating greater value for investors [8][9].